Author/Authors :
Karimi, Mehran Hematology Research Center - Shiraz University of Medical Sciences, Shiraz, Iran , Haghpanah, Sezaneh Hematology Research Center - Shiraz University of Medical Sciences, Shiraz, Iran , Zarei, Tahereh Hematology Research Center - Shiraz University of Medical Sciences, Shiraz, Iran , Azarkeivan, Azita Zafar Adult Thalassemia Clinic - Blood Transfusion Research Center - High Institute for Research and Education in Transfusion Medicine, Tehran, Iran , Shirkavand, Afshan Medical Physicist - Pardis Noor Medical Imaging Center, Tehran, Iran , Matin, Sara Pediatric Department - Jahrom University of Medical Sciences, Jahrom, Iran , Akavan Tavakoli, Maryam Anatomy Sciences Department - Iran University of Medical Sciences, Tehran, Iran , Zahedi, Zohre Hematology Research Center - Shiraz University of Medical Sciences, Shiraz, Iran , De Sanctis, Vincenzo Pediatric and Adolescent Outpatient Clinic - Quisisana Hospital, Ferrara, Italy
Abstract :
Background: Coronavirus disease 2019 (COVID-19) outbreak is a global and challenging disease that is accompany with mortality and morbidity. Aim of study: We evaluated the prevalence and the impact of comorbidities in thalassemia Iranian patients affected by COVID-19. Methods: A multicenter, retrospective, cross-sectional study was conducted across all comprehensive thalassemia centers in Iran, from January to June 15th, 2020. Results: Forty-three confirmed COVID-19 thalassemia patients (32 TDT, and 11 NTDT) were detected. The mean age of patients was 35.3 ± 11.5 years (range 9 - 67); 21 females and 22 males. Over-all, 78.1% of TDT and 90.9% of NTDT patients were complicated with at least one comorbidity (P: 0.656). The overall mortality rate of thalassemia patients with COVID-19 was 18.6% while 27.3% was in NTDT pa-tients compared to 15.6% in TDT patients (P:0.401). The dead group had a non-significant higher frequency of endocrinopathies compared to the recovered group (62.5% versus 45.7% P:0.457). Ten female thalassemia patients with positive COVID-19 had hypogonadism, six patients were receiving hormone replacement ther-apy and all of them recovered (zero death) compared to two deaths from 4 patients who were not receiving hormone replacement therapy (P:0.133). Furthermore, the prevalence of COVID-19 in NTDT patients was significantly higher than the general population (45 per 10,000 versus 22.29 per 10,000 respectively, P:0.018) while the prevalence of TDT was almost similar to the normal population (P:0.539). The mortality rate of COVID-19 was 4.71% in the normal Iranian population compared to 18.6% in β-thalassemias (P: <0.001) at the same date. Conclusions: It is important to acknowledge that β-thalassemia patients, especially young adults/adults, have a chronic condition which may contribute to increase susceptibility to SARS-CoV-2 infection. A higher susceptibility to the infection was observed in patients with NTDT and in untreated hypogonadal female thalassemic patients.However, to confirm these data, more accurate designed studies are needed.
Keywords :
COVID-19 , thalassemias , endocrine disorders , comorbidities , sex steroids